Graft-versus-myeloma effects in reduced-intensity cord blood transplantation

Int J Hematol. 2007 Dec;86(5):463-5. doi: 10.1007/BF02984008.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Busulfan / administration & dosage
  • Cord Blood Stem Cell Transplantation*
  • Disease-Free Survival
  • Female
  • Graft Survival
  • Graft vs Host Disease / prevention & control
  • Graft vs Tumor Effect* / drug effects
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Male
  • Middle Aged
  • Multiple Myeloma / mortality
  • Multiple Myeloma / therapy*
  • Myeloablative Agonists / administration & dosage
  • Remission Induction
  • Retrospective Studies
  • Tacrolimus / administration & dosage
  • Time Factors
  • Transplantation Conditioning*
  • Transplantation, Homologous
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives

Substances

  • Immunosuppressive Agents
  • Myeloablative Agonists
  • Vidarabine
  • Busulfan
  • fludarabine
  • Tacrolimus